Abstract:Abstract Hepatocellular carcinoma (HCC) is a particularly heterogeneous tumor. It has a very poor prognosis. Pyroptosis has been demonstrated in recent years to be an inflammatory form of programmed cell death. However, the relationship between the expression of pyroptosis related genes (PRGs) and prognosis of HCC is still unclear. The development of a specific PRGs prognostic model is important if we want to improve therapeutic effect of tumor. In this study, we identified 42 PRGs that were differentially expressed between HCC and peripheral normal tissues and exhibited the mutation frequency, classification, the location of copy number variation (CNV) alteration and the CNV variation frequency of PRGs. Two clusters were distinguished by the consensus clustering analysis based on the 42 differentially expressed genes (DEGs). The result show that there were significant differences in clinical features (including T stage, grade, gender, stage) among different clusters. KM curve analysis show that cluster 1 had a better prognosis than cluster 2. The prognostic value of PRGs for survival was evaluated to construct a multigene signature using The Cancer Genome Atlas (TCGA) cohort. By applying the univariate analysis and multivariate analysis method, a 10-gene signature was built and all HCC patients in the TCGA cohort were divided into low-risk group and high-risk group. HCC patients in the high-risk group showed significantly lower survival possibilities than those in the low-risk group (P<0.001). Utilizing the median risk score from the TCGA cohort, HCC patients from Gene Expression Omnibus (GEO) cohort (GSE14520) were divided into two risk subgroups. The result showed that overall survival (OS) time was decreased in the high-risk group (P=0.027). Combined with the clinical characteristics, the risk score was found to be an independent factor for predicting the OS of HCC patients. Then, for evaluating the prognostic prediction value of the model, ROC curve and survival analysis were performed. Finally, we constructed a PRGs clinical characteristics nomogram to furtherly predict HCC patient survival probability. There were significant differences in immune cell infiltration, GSEA enrichment pathway, IC50 of chemotherapeutics, PRGs mutation frequency, GO and KEGG analysis between high-risk group and low-risk group. This work suggests PRGs signature plays a crucial role in HCC. The exploration may assist in identifying novel biomarkers and assist HCC patients in predicting their prognosis, clinical diagnosis, and management.

Prediction of Prognosis in Hepatocellular Carcinoma Based on A Gene Signature from Highly Tumorigenic Liver Cancer Cells

A Five-Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients

The Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor microenvironment in Hepatocellular carcinoma

A Seven-Gene Signature to Predict Prognosis of Patients With Hepatocellular Carcinoma

Identification and Validation of a New Gene Signature Predicting Prognosis of Hepatocellular Carcinoma Patients by Network Analysis of Stemness Indices.

Establishment of a Prognostic Model for Hepatocellular Carcinoma Based on Endoplasmic Reticulum Stress-Related Gene Analysis

An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma

Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients

Novel prognostic signature for hepatocellular carcinoma using a comprehensive machine learning framework to predict prognosis and guide treatment

Identification of a Prognostic Transcriptome Signature for Hepatocellular Carcinoma with Lymph Node Metastasis

An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma

Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma

Identification of Novel Gene Signature Associated with Cell Glycolysis to Predict Survival in Hepatocellular Carcinoma Patients

Machine Learning Screens Potential Drugs Targeting a Prognostic Gene Signature Associated With Proliferation in Hepatocellular Carcinoma

Development and Validation of a Novel Prognostic Signature Based on M6a/m5c/m1a-Related Genes in Hepatocellular Carcinoma

Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma

A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma

Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma

Identification of a five-gene signature in association with overall survival for hepatocellular carcinoma

Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-included Resected Hepatocellular Carcinoma Patients

Identification and validation of a novel nine-gene prognostic signature of stem cell characteristic in hepatocellular carcinoma